Jaguar8 commented on a stock · Yesterday 20:04

NEWS

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Thursday, 12th December at 7:00 am
Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population

Strong correlation observed between mRFS and strength of T cell response
Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, presented updated results from the Phase 1 AMPLIFY-201 clinical trial (NCT04853017) of ELI-002, an Amphiphile ("AMP") cancer vaccine that targets KRAS-mutant tumors, at the ESMO Immuno-Oncology Congress 2024 in Geneva, Switzerland.

ELI-002 was evaluated in individuals with mutant KRAS ("mKRAS")-driven colorectal or pancreatic cancer with residual circulating tumor DNA and/or serum tumor biomarkers, who remain at high risk of disease recurrence following standard locoregional treatment.

The updated clinical results, featured in an oral presentationby Shubham Pant, M.D., MBBS, of the University of Texas, MD Anderson Cancer Center, build upon earlier results published in Nature Medicine.

With a median study follow-up of 19.7 months, ELI-002 continues to show a favorable safety profile, the ability to elicit mKRAS-specific T cell responses in most patients, and encouraging efficacy data with respect to mRFS and mOS.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

1154 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

3658Followers

73Following

40KVisitors